PathGroup is committed to providing diagnostic expertise, precision technologies and innovative services and relationships — all to offer clinician partners personalized information for targeted therapies that lead to the best possible patient's outcome.
Led by recognized experts in the field of molecular diagnostics and bioinformatics, PathGroup works with leading individual and contract research partners in developing platforms for improved molecular intelligence. PathGroup molecular diagnostics facility includes a dedicated CLIA validation laboratory to accelerate delivery of new tests and modalities to the physicians and the patients they treat. The portfolio includes several Hematology panels in addition to Endeavor an FDA-cleared test for Molecular Profiling for solid tumors. Endeavor includes a large panel of genes tested by Immunohistochemistry (IHC) and NGS, with a comprehensive report that helps guide clinicians toward beneficial therapies for the patient.